Allergy Diagnostics and Therapeutics Market Size, Share and Growth Outlook, 2026

Allergy Diagnostics and Therapeutics Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Allergy Diagnostics and Therapeutics Market size is forecast to increase from $39.88 Billion in 2026 to $78.3 Billion in 2034 at a CAGR of 8.8% between 2026 and 2034.

The Allergy Diagnostics and Therapeutics market report provides detailed analysis and outlook of Allergy Diagnostics and Therapeutics segments including By Product Type (Allergy Diagnostics, Allergy Therapeutics ), By Test Type (In Vitro Tests, In Vivo Tests ), By Allergen Type (Inhaled Allergens, Food Allergens, Drug Allergens, Venom ), By End-User (Hospitals and Clinics, Diagnostic Laboratories, Academic and Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Allergy Diagnostics and Therapeutics Industry Overview

The Allergy Diagnostics and Therapeutics industry is evolving through advances in targeted immune modulation, changing treatment paradigms for allergic diseases, and ongoing developments in biologic therapies. Pharmaceutical companies, healthcare providers, and research organizations are increasingly focused on therapies that offer more precise immune system regulation while reducing treatment burden and improving long-term patient outcomes. Simultaneously, shifts in product availability and regulatory developments are influencing diagnostic monitoring strategies and patient management approaches across allergy and autoimmune care.

Regulatory Approvals Highlight Allergy-Related Safety Considerations

Regulatory activity continues to influence the broader allergy therapeutics landscape. AbbVie received FDA approval for DECNUPAZ™ (pivekimab sunirine-pvzy) for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. While primarily developed as an oncology therapy, the product includes important labeling information regarding sulfite allergic reactions due to the presence of sodium metabisulfite. The warning is particularly relevant for patients with asthma and other individuals susceptible to sulfite sensitivity. This development highlights the importance of allergy-related safety considerations within pharmaceutical product development and reinforces the role of diagnostic evaluation in identifying patients at risk of adverse hypersensitivity reactions.

Discontinuation of Established Peanut Allergy Therapy Reshaping Patient Management

The industry is also experiencing changes in treatment availability that are influencing clinical practice. Stallergenes Greer announced the discontinuation of Palforzia®, a prescription-only therapy developed for peanut allergy management. The planned withdrawal of this treatment is prompting healthcare professionals and patients to explore alternative therapeutic options and place greater emphasis on ongoing diagnostic monitoring and allergy management strategies. As treatment pathways evolve, diagnostic tools remain essential for assessing patient risk profiles, monitoring allergic responses, and supporting individualized care planning within food allergy management programs.

Targeted Immune Modulation Driving Therapeutic Innovation

A defining trend across the allergy and autoimmune therapeutics market is the transition from broad immunosuppressive approaches toward highly targeted immune modulation strategies. Emerging therapies such as ianalumab for Sjögren's disease and rocatinlimab for atopic dermatitis are being developed to provide more durable clinical responses while reducing treatment burden compared with traditional therapies. These next-generation biologic and immune-targeting treatments aim to selectively influence disease pathways without the extensive systemic effects associated with conventional immunosuppression. As precision medicine principles become increasingly integrated into allergy and autoimmune care, advancements in targeted therapeutics are creating new opportunities for improved disease management and patient outcomes.

Allergy Diagnostics and Therapeutics Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Allergy Diagnostics and Therapeutics market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, Sanofi S.A., Regeneron Pharmaceuticals, Inc., Novartis AG, Stallergenes Greer, ALK-Abelló A/S, HollisterStier Allergy (Jubilant Pharma), Omega Diagnostics Group PLC. The Allergy Diagnostics and Therapeutics market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Allergy Diagnostics and Therapeutics industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Allergy Diagnostics and Therapeutics Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Allergy Diagnostics and Therapeutics companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Allergy Diagnostics and Therapeutics markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Allergy Diagnostics and Therapeutics Market Competitive Benchmarking and Company Analysis

Leading companies in Allergy Diagnostics and Therapeutics industry include- Thermo Fisher Scientific Inc., Siemens Healthineers AG, Danaher Corporation, Sanofi S.A., Regeneron Pharmaceuticals, Inc., Novartis AG, Stallergenes Greer, ALK-Abelló A/S, HollisterStier Allergy (Jubilant Pharma), Omega Diagnostics Group PLC. The Allergy Diagnostics and Therapeutics market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Allergy Diagnostics and Therapeutics Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Allergy Diagnostics and Therapeutics market remains one of the strongest-performing segments in the country.
The US Allergy Diagnostics and Therapeutics Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Allergy Diagnostics and Therapeutics market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Allergy Diagnostics and Therapeutics industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Allergy Diagnostics and Therapeutics markets

Canada's strong Allergy Diagnostics and Therapeutics sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Allergy Diagnostics and Therapeutics market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Allergy Diagnostics and Therapeutics Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Allergy Diagnostics and Therapeutics market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Allergy Diagnostics and Therapeutics population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Allergy Diagnostics and Therapeutics industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Allergy Diagnostics and Therapeutics market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Allergy Diagnostics and Therapeutics sales through 2034

France Allergy Diagnostics and Therapeutics companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Allergy Diagnostics and Therapeutics Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Allergy Diagnostics and Therapeutics distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Allergy Diagnostics and Therapeutics Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Allergy Diagnostics and Therapeutics market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Allergy Diagnostics and Therapeutics industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Allergy Diagnostics and Therapeutics industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Allergy Diagnostics and Therapeutics Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Allergy Diagnostics and Therapeutics market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Allergy Diagnostics and Therapeutics market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Allergy Diagnostics and Therapeutics Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Allergy Diagnostics and Therapeutics Market Segmentation

By Product Type
Allergy Diagnostics
Allergy Therapeutics
By Test Type
In Vitro Tests
In Vivo Tests
By Allergen Type
Inhaled Allergens
Food Allergens
Drug Allergens
Venom
By End-User
Hospitals and Clinics
Diagnostic Laboratories
Academic and Research Institutes

Top Companies in Allergy Diagnostics and Therapeutics Industry

Thermo Fisher Scientific Inc.
Siemens Healthineers AG
Danaher Corporation
Sanofi S.A.
Regeneron Pharmaceuticals, Inc.
Novartis AG
Stallergenes Greer
ALK-Abelló A/S
HollisterStier Allergy (Jubilant Pharma)
Omega Diagnostics Group PLC

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025